Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hepatic decompensation (some fatal) has occurred in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking